Precision BioSciences Inc. (DTIL) PT Lowered to $19 at Jefferies, but 'near-term setup is attractive'

Jefferies analyst Maury Raycroft lowered the price target on Precision BioSciences Inc. (NASDAQ: DTIL) to $19.00 (from $21.00) while maintaining a Buy rating.

The analyst commented, "Near-term setup is attractive w/ 2 very differentiated programs: 1) HBV ph.I progressing well through dose escalation and data this yr @ med conferences focused on safety, stopping NUCs, testing for functional cure, and moving into Part 2 expansion cohorts; 2) DMD IND cleared in early '26 w/ initial data from multiple pts by YE26; KOL event 3/17 @ 9AM ET. Cash through 2028 beyond multiple clin inflection points."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Boeing lands two U.S. defense contracts worth over $711M
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027